|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | |||||||||||
| Cash | |||||||||||
| Prepaid expenses | |||||||||||
| Total current assets | |||||||||||
| Prepaid expenses—non-current | |||||||||||
| Investments and cash held in Trust Account | |||||||||||
| Total non-current assets | |||||||||||
| Total Assets | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | |||||||||||
| Accrued expenses | |||||||||||
| Extension payment payable | |||||||||||
| Advances from Webull | |||||||||||
| Sponsor Note | |||||||||||
| Ordinary Class A shares to be redeemed | |||||||||||
| Overfunding loan | |||||||||||
| Total current liabilities | |||||||||||
| Non-current liabilities: | |||||||||||
| Derivative liability | |||||||||||
| Overfunding loan | |||||||||||
| Deferred underwriting commissions and advisory fees | |||||||||||
| Deferred underwriting and advisory fees | |||||||||||
| Total non-current liabilities | |||||||||||
| Total liabilities | |||||||||||
| Class A ordinary shares, $0.0001 par value; 9,000,000,000 shares authorized; 9,732,960 and 10,056,597 shares subject to possible redemption at approximately $11.57 and $10.89 per share as of December 31, 2024 and 2023, respectively | |||||||||||
| Shareholders’ Deficit: | |||||||||||
| Common stock, value | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | |||||||||||
| Total shareholders’ deficit | |||||||||||
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit |
Loading...
